Newly identified biomarkers help predict outcome in idiopathic pulmonary fibrosis

A Yale-led study has identified a gene expression profile that can predict outcomes and lead to better treatment for one of the most lethal lung diseases, idiopathic pulmonary fibrosis (IPF). The study appears in Science Translational Medicine.

IPF causes progressive scarring of the lungs, leading to cough, shortness of breath, and potentially death. In most cases, the cause cannot be identified, and there is no cure other than a . While some patients experience a progressive course that leads to death within one to two years, others experience a relative stable disease.

The researchers' goal was to identify changes in expression of genes in the blood that are predictive of poor outcomes among patients with IPF.

Using two cohorts of patients, the researchers from Yale, University of Chicago, and University of Pittsburgh analyzed the expression of the genes in the whole genome of patients with IPF, and identified 52 genes that significantly correlated with outcome. They further found that the decreased expression of four genes—CD28, ICOS, LCK, and ITK—predicted shorter survival time in patients with IPF.

The research team believes discovery of these biomarkers will help physicians better predict disease presence, severity, and prognosis in IPF patients. "Given the fact that is the only therapy that has shown to improve survival in IPF, our test could allow physicians to refer IPF patients for lung transplant at the right time—not too late and not too early," said senior and corresponding author Naftali Kaminski, M.D., professor and chief of pulmonary, critical care, and sleep medicine at Yale School of Medicine.

This video is not supported by your browser at this time.
John Morthanos, a patient with IPF who has undergone a lung transplant, describes his experience with the disease and the impact a blood test will have. Credit: Mathur, A. Herazo-May, J. Kaminski, N. Herzog, E. - Pulmonary, Critical Care and Sleep Medicine, Yale School of Medicine

Right now, at least six drugs are being studied for IPF. First author Jose Herazo-Maya of Yale School of Medicine said that one of the study's major impacts would be on drug studies. "Current drug studies do not address the variability in outcomes of IPF patients," he said. "Our findings may help investigators target who are more likely to progress and improve."

The decreased genes that predicted shorter survival time were mostly related to immune activation. Author Imre Noth, leader of the University of Chicago team, said, "Our result may also shed light on disease mechanisms, by supporting the emerging notion that aberrant immunity may play a role in IPF."

More information: "Peripheral Blood Mononuclear Cell Gene Expression Profiles Predict Poor Outcome in Idiopathic Pulmonary Fibrosis," by J.D. Herazo-Maya et al. Science Translational Medicine, 2013.

Related Stories

Gene study helps understand pulmonary fibrosis

Apr 16, 2013

A new study looking at the genomes of more than 1,500 patients with idiopathic pulmonary fibrosis, a rare and devastating lung disease, found multiple genetic associations with the disease, including one gene variant that ...

Finding cellular causes of lung-hardening disease

Sep 17, 2013

(Medical Xpress)—Idiopathic Pulmonary Fibrosis, or IPF, is an incurable lung disease that, over time, turns healthy lung tissue into inflexible scar tissue – hardening the lungs and eventually causing ...

Recommended for you

WHO: Number of Ebola cases passes 10,000

36 minutes ago

The number of people believed sickened by Ebola has passed 10,000, according to figures released Saturday by the World Health Organization, as the outbreak continues to spread.

NY and NJ say they will require Ebola quarantines

12 hours ago

The governors of New Jersey and New York on Friday ordered a mandatory, 21-day quarantine for all doctors and other arriving travelers who have had contact with Ebola victims in West Africa.

User comments